Agenus Inc. (NASDAQ:AGEN)’s share price rose 4.7% during trading on Friday . The stock traded as high as $6.23 and last traded at $6.22, with a volume of 1,142,314 shares trading hands. The stock had previously closed at $5.94.

AGEN has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Agenus in a research report on Sunday, July 31st. Maxim Group reiterated a “buy” rating and issued a $7.00 price target on shares of Agenus in a research note on Friday, June 10th. Jefferies Group boosted their price target on Agenus from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Finally, Zacks Investment Research upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Agenus has an average rating of “Buy” and a consensus price target of $10.25.

The firm’s market capitalization is $540.59 million. The firm has a 50 day moving average of $4.96 and a 200-day moving average of $4.03.

Agenus (NASDAQ:AGEN) last posted its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. The firm had revenue of $6.59 million for the quarter, compared to the consensus estimate of $5.12 million. On average, equities analysts anticipate that Agenus Inc. will post ($1.27) EPS for the current fiscal year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.